Table 1. Patient baseline and disease characteristics.
| Characteristic | n (%) | ||
| Dose-escalation
(N=15) |
Dose-expansion
(N=15) |
Total | |
| ECOG PS, Eastern Cooperative Oncology Cohort performance status; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALK+ALCL, anaplastic large-cell lymphoma, ALK-positive; ALK−ALCL, anaplastic large-cell lymphoma, ALK-negative; LDH, lactate dehydrogenase; IPI, international prognostic index. *, nodal peripheral T-cell lymphoma with T follicular helper phenotype, 1 patient; Mycosis fungoides, 1 patient; primary cutaneous anaplastic large cell lymphoma, 1 patient. | |||
| Age (year) [median (range)] | 47.0 (38.0, 58.0) | 55.0 (49.0, 62.0) | 52.5 (42.0, 58.0) |
| Sex | |||
| Male | 9 (60.0) | 10 (66.7) | 19 (63.3) |
| Female | 6 (40.0) | 5 (33.3) | 11 (36.7) |
| ECOG PS | |||
| 0 | 9 (60.0) | 9 (60.0) | 18 (60.0) |
| 1 | 6 (40.0) | 6 (40.0) | 12 (40.0) |
| Ann Arbor stage III/IV | 9 (60.0) | 10 (66.7) | 19 (63.3) |
| Pathological subtype | |||
| PTCL-NOS | 8 (53.3) | 4 (26.7) | 12 (40.0) |
| AITL | 1 (6.7) | 7 (46.7) | 8 (26.7) |
| ALK+ALCL | 3 (20.0) | 1 (6.7) | 4 (13.3) |
| ALK−ALCL | 1 (6.7) | 2 (13.3) | 3 (10.0) |
| *Others | 2 (13.3) | 1 (6.7) | 3 (10.0) |
| LDH elevated | 3 (20.0) | 5 (33.3) | 8 (26.7) |
| B symptoms presence | 5 (33.3) | 5 (33.3) | 10 (33.3) |
| IPI risk group | |||
| 0−1 | 11 (73.3) | 7 (46.7) | 18 (60.0) |
| ≥2 | 4 (26.7) | 8 (53.3) | 12 (40.0) |
| Extranodal involvement | 5 (33.3) | 6 (40.0) | 11 (36.7) |